Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,576.87 60.60 0.42%
TOPIX 1,178.44 5.07 0.43%
HANG SENG 22,760.24 64.23 0.28%

Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid Imaging Agent Presented at AAIC 2013



  Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid
  Imaging Agent Presented at AAIC 2013

 – Comparative Results from Alzheimer’s Disease (AD) Post-Mortem Tissue Study
              Presented by McGill Center for Studies in Aging –

Business Wire

DUBLIN, Ohio -- July 22, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that
researchers at McGill Center for Studies in Aging, Douglas Research Institute
and Montreal Neurological Institute presented results of a post-mortem brain
tissue study using Navidea’s investigational Fluorine-18 labeled β-amyloid
imaging agent, NAV4694, during the Alzheimer's Association International
Conference (AAIC) in Boston, MA. The study comparing performance
characteristics of NAV4694 to the gold-standard imaging agent, ^11C-labeled
Pittsburgh Compound-B (PiB), in control and AD brain tissue concluded that
although the molecules share structural similarity, NAV4694 better
differentiated amyloid deposition associated with AD in post-mortem brains
than PiB.^1

“Our research indicates that NAV4694 shows strong performance characteristics
as an amyloid imaging agent for AD research and clinical use,” said Pedro
Rosa-Neto MD, PhD, Assistant Professor of Neurology, Neurosurgery and
Psychiatry at McGill University, Quebec, Canada. “This study indicated that
unlike PiB, the benchmark PET amyloid agent, NAV4694 was capable of
differentiating controls from AD in all brain regions and also exhibited a
wider dynamic range and fewer false negatives as compared to gold-standard
pathology.”

“We are very pleased that the McGill research team has shared these data with
our colleagues and the scientific community at AAIC,” said Connie Reininger,
MD, PhD, Navidea’s Senior Vice President and Chief Medical Officer. “We remain
committed to providing physicians and patients an improved diagnostic agent
that can aid in the differential diagnosis of Alzheimer's disease and other
forms of neurodegenerative dementia. These results further support the
recently announced AIBL decision to utilize NAV4694 in place of PiB in their
comprehensive research initiative in AD and Mild Cognitive Impairment.”

^1 The study entitled, “[18F]NAV4694 shows higher binding and wider dynamic
range compared to [11C]PIB in Alzheimer’s disease post-mortem tissue” was
presented as a poster by E. Zimmer et al on Tuesday, July 16, 2013 at
Alzheimer's Association International Conference (AAIC). The study included
analysis of 25 Control (age=74.6+/-11.7) and 13 AD (age=75.3+/-8.6) human
post-mortem brain samples containing the prefrontal cortex, hippocampus,
posterior cingulate cortex, inferior parietal cortex and striatum regions.

About NAV4694

NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate
intended for use in Positron Emission Tomography (PET) imaging and evaluation
of patients with signs or symptoms of cognitive impairment such as Alzheimer’s
disease (AD). NAV4694 binds to β-amyloid deposits in the brain that can then
be imaged in scans. β-amyloid plaque pathology is widely used in the diagnosis
of AD. The ability of NAV4694 imaging to display amyloid plaque pathology may
enable earlier identification of AD and improve monitoring of disease
progression and interpretation of brain scan images. Navidea has an ongoing
NAV4694 Phase 2b trial in Mild Cognitive Impairment and a Phase 3 program for
NAV4694 in AD.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, and markets for
the Company’s products are forward-looking statements within the meaning of
the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not
limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing
and manufacturing experience, risks of development of new products, regulatory
risks and other risks detailed in the Company’s most recent Annual Report on
Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking
statements.

Contact:

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement